HER2-Positive Conversion in a Metastatic Liver Focus in Late Recurrent Breast Cancer
Late recurrence of estrogen receptor (ER) positive breast cancer is common. When tissues from a recurrent or metastatic focus are available, re-evaluation of ER, progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) status is recommended for treatment selection. This case...
Main Authors: | Miyuki Kitahara, Yasuo Hozumi, Ayaka Nakamura, Kana Tachi, Hitoaki Saitoh, Tatsuo Iijima |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2019-06-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/501306 |
Similar Items
-
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
by: Alberto Ocaña, et al.
Published: (2020-01-01) -
The Prognostic Impact of HER2 Genetic and Protein Expression in Pancreatic Carcinoma—HER2 Protein and Gene in Pancreatic Cancer
by: Song-Hee Han, et al.
Published: (2021-04-01) -
Quantification of Cell-free HER-2 DNA in Plasma from Breast Cancer Patients: Sensitivity for Detection of Metastatic Recurrence and Gene Amplification
by: Patricia Diana Sørensen, et al.
Published: (2015-08-01) -
A case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy after primary treatment of triple-negative breast cancer
by: Haruta Rumi, et al.
Published: (2011-11-01) -
Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications
by: Ana Godoy-Ortiz, et al.
Published: (2019-10-01)